Publications by authors named "Markus Goettel"

Claim this Profile
P
Phase 1 studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 690517 (vicadrostat), a novel aldosterone synthase inhibitor, in healthy male volunteers.
Friedrich Schulze, Jennifer Schaible, Markus Goettel, Yuko Tanaka, Kathrin Hohl

Naunyn Schmiedebergs Arch Pharmacol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies.
René Fuertig, Markus Goettel, Lena Herich, Josef Hoefler, Sabrina T Wiebe

CNS Drugs· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males.
Markus Goettel, Rene Fuertig, Salome Rebecca Mack, Stefan Just, Vikas Sharma

CNS Drugs· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor.
Michael Desch, Glen Wunderlich, Markus Goettel, Sophia Goetz, Karl-Heinz Liesenfeld

Eur J Drug Metab Pharmacokinet· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Midazolam microdosing applied in early clinical development for drug-drug interaction assessment.
Sabrina T Wiebe, Andreas Huennemeyer, Werner Kadus, Markus Goettel, Alen Jambrecina

Br J Clin Pharmacol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis